Cargando…

Pharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling

Lifestyle factors are important drivers of chronic diseases, including cardiovascular syndromes, with low grade inflammation as a central player. Attenuating myeloperoxidase (MPO) activity, an inflammatory enzyme associated with obesity, hypertension and heart failure, could have protective effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piek, Arnold, Koonen, Debby P. Y., Schouten, Elisabeth-Maria, Lindtstedt, Eva L., Michaëlsson, Erik, de Boer, Rudolf A., Silljé, Herman H. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904581/ https://www.ncbi.nlm.nih.gov/pubmed/31822739 http://dx.doi.org/10.1038/s41598-019-55263-y

Ejemplares similares

The role of myeloperoxidase and myeloperoxidase–antineutrophil cytoplasmic antibodies (MPO-ANCAs) in the pathogenesis of human MPO-ANCA-associated glomerulonephritis
por: Arimura, Yoshihiro, et al.
Publicado: (2013)

The Enzymatic and Non-Enzymatic Function of Myeloperoxidase (MPO) in Inflammatory Communication
por: Kargapolova, Yulia, et al.
Publicado: (2021)

Temporal Dissociation between Myeloperoxidase (MPO)-Modified LDL and MPO Elevations during Chronic Sleep Restriction and Recovery in Healthy Young Men
por: Zouaoui Boudjeltia, Karim, et al.
Publicado: (2011)

Examining Myeloperoxidase (MPO) biomarker in the saliva of patients with Lactobacillus-associated caries in Hilla City
por: Hessan, Hanan Selman, et al.
Publicado: (2023)

Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice
por: Koop, Anja Christina, et al.
Publicado: (2020)

A combined bioinformatics, experimental and clinical approach to identify novel cardiac‐specific heart failure biomarkers: is Dickkopf‐3 (DKK3) a possible candidate?
por: Piek, Arnold, et al.
Publicado: (2020)

SNP rs2243828 in MPO associated with myeloperoxidase level and atrial fibrillation risk in Chinese Han population
por: Wang, Pengyun, et al.
Publicado: (2020)

Flexible Amperometric Immunosensor Based on Colloidal Quantum Dots for Detecting the Myeloperoxidase (MPO) Systemic Inflammation Biomarker
por: Tao, Yanbing, et al.
Publicado: (2023)

A case of myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-associated glomerulonephritis and concurrent membranous nephropathy
por: Shimada, Michiko, et al.
Publicado: (2013)

High prevalence of Chlamydophila pneumoniae infection in patients with myeloperoxidase antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated glomerulonephritis
por: Kawaguchi, Takehiko, et al.
Publicado: (2008)

From Kidney to Brain: An Uncommon Severe Relapse of Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibody (MPO-ANCA) Vasculitis
por: Araújo, Tiago, et al.
Publicado: (2021)

AKIP1 Expression Modulates Mitochondrial Function in Rat Neonatal Cardiomyocytes
por: Yu, Hongjuan, et al.
Publicado: (2013)

Targeting Myeloperoxidase (MPO) Mediated Oxidative Stress and Inflammation for Reducing Brain Ischemia Injury: Potential Application of Natural Compounds
por: Chen, Shuang, et al.
Publicado: (2020)

The emerging plasma biomarker Dickkopf-3 (DKK3) and its association with renal and cardiovascular disease in the general population
por: Piek, Arnold, et al.
Publicado: (2021)

Regulation of the (pro)renin–renin receptor in cardiac remodelling
por: Mahmud, Hasan, et al.
Publicado: (2012)

From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities
por: Suthahar, Navin, et al.
Publicado: (2017)

Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production
por: Du, Weijie, et al.
Publicado: (2018)

Circulating Myeloperoxidase (MPO)-DNA complexes as marker for Neutrophil Extracellular Traps (NETs) levels and the association with cardiovascular risk factors in the general population
por: Donkel, Samantha J., et al.
Publicado: (2021)

Therapeutic inhibition of MPO stabilizes pre-existing high risk atherosclerotic plaque
por: Chen, Weiyu, et al.
Publicado: (2022)

Menopausal Status Modifies Breast Cancer Risk Associated with the Myeloperoxidase (MPO) G463A Polymorphism in Caucasian Women: A Meta-Analysis
por: Pabalan, Noel, et al.
Publicado: (2012)

Evaluation of the Biological Effects of Lyophilized Hydrophilic Extract of Rhus coriaria on Myeloperoxidase (MPO) Activity, Wound Healing, and Microbial Infections of Skin Wound Tissues
por: Gabr, Sami A., et al.
Publicado: (2019)

Myeloperoxidase Is an Early Biomarker of Inflammation and Cardiovascular Risk in Prepubertal Obese Children
por: Olza, Josune, et al.
Publicado: (2012)

Investigating the Role of Myeloperoxidase and Angiopoietin-like Protein 6 in Obesity and Diabetes
por: Qaddoumi, Mohammad G., et al.
Publicado: (2020)

An Autopsy Case of Myeloperoxidase-anti-neutrophil Cytoplasmic Antibody (MPO-ANCA)-associated Vasculitis Accompanied by Cryoglobulinemic Vasculitis Affecting the Kidneys, Skin, and Gastrointestinal Tract
por: Hasegawa, Jumpei, et al.
Publicado: (2018)

MPO-ANCA crescentic glomerulonephritis complicated by membranous nephropathy: MPO demonstrated in epimembranous deposits
por: Matsumoto, Kei, et al.
Publicado: (2009)

Myeloperoxidase: A Therapeutic Target for Preventing Insulin Resistance and the Metabolic Sequelae of Obesity?
por: Heinecke, Jay W., et al.
Publicado: (2014)

Myeloperoxidase Deletion Prevents High-Fat Diet–Induced Obesity and Insulin Resistance
por: Wang, Qilong, et al.
Publicado: (2014)

Association between Myeloperoxidase Levels and Risk of Insulin Resistance in Egyptian Obese Women
por: Zaki, Moushira, et al.
Publicado: (2018)

Protective Effects of Therapeutic Neutrophil Depletion and Myeloperoxidase Inhibition on Left Ventricular Function and Remodeling in Myocardial Infarction
por: Guthoff, Henning, et al.
Publicado: (2022)

Flow cytometry lyophilised-reagent tube for quantifying peripheral blood neutrophil myeloperoxidase expression in myelodysplastic syndromes (MPO-MDS-Develop): protocol for a diagnostic accuracy study
por: Raskovalova, Tatiana, et al.
Publicado: (2022)

The fibrosis-cell death axis in heart failure
por: Piek, A., et al.
Publicado: (2016)

LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes
por: Cannon, Megan V., et al.
Publicado: (2015)

Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction
por: Yurista, Salva R., et al.
Publicado: (2020)

Pharmacologic IRE1/XBP1s activation promotes systemic adaptive remodeling in obesity
por: Madhavan, Aparajita, et al.
Publicado: (2022)

Effect of obesity reduction on preservation of heart function and attenuation of left ventricular remodeling, oxidative stress and inflammation in obese mice
por: Wang, Hui-Ting, et al.
Publicado: (2012)

Released Myeloperoxidase Attenuates Neutrophil Migration and Accumulation in Inflamed Tissue
por: Rehring, Jacob F., et al.
Publicado: (2021)

Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated With Disease Severity in COVID-19 Patients
por: Shrivastava, Shubham, et al.
Publicado: (2021)

Evaluation of renal cancer progression in a mouse model of heart failure
por: Shi, Canxia, et al.
Publicado: (2021)

Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction
por: Ali, Muhammad, et al.
Publicado: (2016)

Pharmacologic Treatment of Obesity
por: Halpern, Alfredo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_qccuvrqh8tdk38oln1gghdtipq